Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for islet cell transplantation in the context of a clinical trial, with an effective date of May 15, 2026. Here's what billing teams need to know before that date arrives.
CMS islet cell transplantation coverage policy has been a narrow, tightly controlled area for years. This modification touches a procedure that only covers patients enrolled in qualifying clinical trials — meaning your documentation burden is high, your billing guidelines need to be precise, and a single misstep on medical necessity will cost you on the back end. The policy does not list specific CPT or HCPCS codes in the available data, which we'll address directly in the codes section below.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Islet Cell Transplantation in the Context of a Clinical Trial |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | High |
| Specialties Affected | Transplant surgery, endocrinology, clinical trial coordinators, hospital outpatient billing |
| Key Action | Audit your clinical trial documentation and medical necessity records before May 15, 2026 |
CMS Islet Cell Transplantation Coverage Criteria and Medical Necessity Requirements 2026
The CMS islet cell transplantation coverage policy has always been conditional. Coverage is not available for islet cell transplantation as a routine procedure. CMS covers it only when it occurs within an approved clinical trial setting.
This is the central medical necessity requirement — and it's non-negotiable. The patient must be enrolled in a qualifying clinical trial. Your documentation must show that clearly, or you're looking at a claim denial before the reviewer even reaches the clinical criteria.
The practical implication here is that your billing team isn't just doing billing. You're doing compliance documentation at the same time. The clinical trial enrollment records, the trial's CMS approval status, and the patient's eligibility within that trial all feed directly into your reimbursement claim.
CMS has historically tied this coverage to the broader framework of its Clinical Trial Policy. That means the trial itself must meet specific standards — it must be designed to produce meaningful clinical evidence, and the procedure must be integral to the trial, not incidental to it. If the transplant is happening alongside a trial but isn't a core part of it, coverage is at risk.
Prior authorization requirements for clinical trial procedures under Medicare are uncommon in the traditional sense, but don't confuse that with the absence of preconditions. The preconditions here are just embedded in the trial participation and documentation requirements rather than a separate prior auth workflow. Your billing team needs to treat clinical trial enrollment verification as the functional equivalent of prior authorization — it has to happen before the claim goes out.
Medical necessity, in this context, means two things simultaneously. First, the patient must have a medical condition that islet cell transplantation is designed to address. Second, the clinical trial must be the appropriate setting for delivering that treatment. Both conditions have to be met and documented. One without the other isn't sufficient.
CMS Islet Cell Transplantation Exclusions and Non-Covered Indications
CMS does not cover islet cell transplantation outside of a qualifying clinical trial. That's the primary exclusion — and it's categorical.
If a patient receives an islet cell transplant as a standard-of-care procedure, Medicare won't pay. No exceptions documented in current policy. This isn't a gray area.
The same applies to trials that don't meet CMS's standards for clinical trial coverage. A study sponsored by a private institution isn't automatically qualifying. CMS requires trials to meet specific criteria — typically that they're approved or funded by recognized entities such as the National Institutes of Health, a cooperative group, or a similar body. If your facility is participating in a trial that doesn't meet those criteria, the transplant procedure won't be covered even if every other documentation requirement is met.
Islet cell transplantation billing outside of this specific clinical trial context is not a path to reimbursement under Medicare. If your team is seeing requests to bill this procedure outside a trial, flag it immediately. That's a compliance issue, not just a billing one.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Islet cell transplantation performed as part of a qualifying clinical trial | Covered | Not specified in available policy data | Trial must meet CMS clinical trial coverage standards; full documentation required |
| Islet cell transplantation outside of a qualifying clinical trial | Not Covered | Not specified in available policy data | Categorical exclusion; no exceptions documented |
| Islet cell transplantation in a non-qualifying or non-approved trial | Not Covered | Not specified in available policy data | Trial approval status must be verified before billing |
CMS Islet Cell Transplantation Billing Guidelines and Action Items 2026
This modification has a hard effective date of May 15, 2026. Here's what to do before then.
| # | Action Item |
|---|---|
| 1 | Verify clinical trial approval status for every active case. Before May 15, 2026, confirm that any trial your facility participates in meets CMS's qualifying criteria. Get written confirmation from your clinical research office. Don't assume — check. |
| 2 | Audit your medical necessity documentation process. Your documentation needs to show both the patient's medical condition and the integral role of the transplant within the trial. If your current templates don't capture both, revise them now. A claim denial on a transplant procedure is a significant revenue hit. |
| 3 | Align with your clinical trial coordinators. Islet cell transplantation billing doesn't sit in a single department. Your billing team, your transplant coordinators, and your research compliance office all need to be working from the same documentation checklist. Set that meeting before May 15, 2026. |
| 4 | Review your charge capture workflow for clinical trial procedures. Make sure your charge capture system flags islet cell transplantation claims for secondary review. These claims need a compliance check before submission — not after a denial comes back. |
| 5 | Confirm your payer mix exposure. This is a Medicare policy change. If you have patients receiving islet cell transplantation through Medicare Advantage plans, check with those payers separately. Medicare Advantage plans are not always required to follow traditional Medicare coverage policy on clinical trial procedures — the rules there can vary. |
| 6 | Talk to your compliance officer if you're unsure about trial qualification. The line between a qualifying and non-qualifying trial isn't always obvious from the billing side. If there's any ambiguity about whether your trial meets CMS standards, loop in your compliance officer before the effective date — not after a claim comes back denied. |
| 7 | Document the modification itself in your policy tracking log. This is a modified policy, not a new one. That means the previous version's requirements still matter for claims dating before May 15, 2026. Keep both versions accessible for any retrospective audits. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Islet Cell Transplantation Under This Policy
The available policy data does not list specific CPT, HCPCS, or ICD-10 codes. This is not unusual for CMS national coverage determinations that center on clinical trial participation — the applicable codes depend on the specific procedures performed within the trial context, and CMS often leaves code-level specificity to the Medicare Administrative Contractor level.
What This Means for Your Billing Team
The absence of a published code list in this policy does not mean there are no applicable codes. It means you need to work from CMS's broader clinical trial billing guidance and from your MAC's local coverage determinations to identify the correct codes for your specific situation.
Contact your Medicare Administrative Contractor directly to confirm which codes they expect on claims for islet cell transplantation within a qualifying clinical trial. MACs handle the claim-level processing, and their guidance on code requirements is what your billing team will actually be held to.
Do not attempt to infer codes from similar transplant procedures without MAC confirmation. Transplant billing is a high-audit area. Wrong codes on a transplant claim don't just get denied — they can trigger medical review.
If your billing consultant or coding team has access to the full policy version published on the CMS website, cross-reference that document for any code-level guidance that may not have been captured in the summary available here. The source document for this policy is available at PayerPolicy: https://app.payerpolicy.org/p/cms/286-v1.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.